Varizig Lyophilisate For Solution For Injection 125iu Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

VARIZIG: Lyophilisate for solution for injection (125IU)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

VARICELLA-ZOSTER IMMUNE GLOBULIN (var uh SEL uh - ZOS ter i MYOON GLOB yoo lin) helps to reduce the severity of chickenpox infections in patients who are at risk. This medicine is collected from the pooled blood of many donors.

In-Depth Information

VariZIG 125units Powder for Solution for Injection

NDC: 532700125
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Varicella (chickenpox) Infection Prophylaxis

Storage Information
Use within 12 hours after reconstitution
Discard unused portion. Do not store for later use.
Do not freeze
Store between 36 to 46 degrees F
VariZIG 125units Powder for Solution for Injection

Reported Side Effects for VariZIG 125units Powder for Solution for Injection

Tired Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Serum Sickness Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Chills Incidence:
<2.0%*
Severity: MILD
Onset: RAPID
Headache Incidence:
2.0-4.0%*
Severity: MILD
Onset: EARLY
Injection Site Reaction Incidence:
2.0-9.0%*
Severity: MILD
Onset: RAPID
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with VARIZIG

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5